Pareen Vora

Epidemiologist - Cardiovascular @BayerPharma

[Pareen Vora @pareenvora]

See our new publication on the importance of Understanding Causes of Death in Patients With ARDS https://t.co/aZGcbQ0NVC

[Pareen Vora @pareenvora]

#TopCitedArticle

[Pareen Vora @pareenvora]

Great to see the impact of our work on Pulmonary thromboembolic events in COVID-19 which was published in Pulmonary Circulation is now one of their top 10 most-cited papers for 2022-23!
https://t.co/abdmy72Tvt

[Pareen Vora @pareenvora]

Characteristics of adults with potential refractory chronic cough identified using an algorithm designed for administrative claims databases: A descriptive study
https://t.co/XrkgZgunsp

[Pareen Vora @pareenvora]

@yeysus

[Pareen Vora @pareenvora]

See our new publication of study design of a prospective study on persistence and adherence. https://t.co/eC5Mf7DuM5

[Pareen Vora @pareenvora]

See our recent publication summarizing the global epidemiology of gastrointestinal bleeding in general population
https://t.co/22MSoSdghl

[BMJ_Open @BMJ_Open]

Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study - https://t.co/BCKa0zROD4

[Pareen Vora @pareenvora]

Read our publication on CardioAspirin and Gastrointestinal Cancer prevention in Hong Kong https://t.co/TsgCPlNO81

[Pareen Vora @pareenvora]

Read our publication on Oral Anticoagulants utilization trends in 5 countries and 9 data sources using #TreatmentPathway tool and #ATLAS #OHDSI #OMOP #CDM #LargeScaleAnalytics #DataVisualization https://t.co/kdwGEn7uhN via @Hindawi

[Pareen Vora @pareenvora]

Gender Stereotypes | Zoe Cash | TEDxYouth@BerlinCosmopolitanSchool https://t.co/kjmiC5Ri2c via @YouTube

[Pareen Vora @pareenvora]

Read our publication on the public health impact of low-dose aspirin! https://t.co/6hsV8c2omb

[Pareen Vora @pareenvora]

Read more about our study published as open access in The Patient - Patient Centered Outcomes Research.
https://t.co/P8dBfCIdAM

[Pareen Vora @pareenvora]

Validation of venous thromboembolism diagnoses in patients receiving rivaroxaban or warfarin in The Health Improvement Network https://t.co/U8OH4UpN2b

[Pareen Vora @pareenvora]

Thirty-Year Incidence and Mortality Trends in Gastrointestinal Bleeding in Finland https://t.co/xIudNGEM3T via @JAMANetworkOpen part of @JAMANetwork

[Miguel Hernán @_MiguelHernan]

1/ We don't have a vaccine yet, but we have a treatment that may reduce the risk of #COVID19 by 20% without serious side effects.

That treatment is #hydroxychloroquine.

Risk ratio of COVID-19 in our meta-analysis of 3 prophylaxis randomized trials: 0.78
https://t.co/OPE9tCEx0y

[Miguel Hernán @_MiguelHernan]

4/ Update #1

The findings from a fourth randomized trial were published today. They change neither the risk ratio estimate nor our conclusion:

We need additional randomized trials to obtain a more precise estimate of the effect of #hydroxychloroquine, overall and in subgroups.

[Jesus del Valle @yeysus]

#Clinicaltrials rebound after COVID-19 crash, but can enrollment gains continue? https://t.co/B2mzV2ai2O @pareenvora @SuzartK @alexhabs @mrpusch

[Pareen Vora @pareenvora]

@yeysus @SuzartK @FariqRed @Bayer @YoSoyMayonesa @jotka @KYepitsme @alexhabs @MaikelMoheb @JulesHitz @mrpusch @VanessaLemarie Can you send me the link? I would like to try as well.

[Pareen Vora @pareenvora]

@yeysus @FariqRed @Bayer @YoSoyMayonesa @jotka @SuzartK @KYepitsme @alexhabs @MaikelMoheb @JulesHitz @mrpusch @VanessaLemarie Why a sad smiley? 😬